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A COST—EFFECTIVENESS ANALYSIS MODEL FOR
TREATMENT OF CANDIDIASIS AND INVASIVE
ASPERGILLOSIS IN MEXICO
Mould Quevedo JF, Contreras I, García—Contreras F, Nevarez A,
Constantino—Casas P, Garduño J
Social Security Mexican Institute, México D.F, México D.F, Mexico
OBJECTIVES: The purpose of this research is to estimate the
incremental cost–effectiveness ratio (ICER) in Mexican patients
with candidiasis and aspergillosis treated within voriconazole,
amphotericin B and caspofungine. METHODS: It has been
carried out a cost–effectiveness analysis based on a decision
model represented with a decision tree describing multiple ther-
apeutic options together with the obtained clinical results and
the associated costs. The data come from clinical literature for
treatment of candidiasis and invasive aspergillosis in immun-
odepressed patients. Effectiveness measure was the number of
patients with therapeutic success. Costs were taken from hospi-
tal records and expert opinion. The perspective was that of the
National health provider (only direct medical costs) and the time
horizon of the research is of 3 months. The sensitivity analysis
was probabilistic and acceptability curves were constructed.
RESULTS: On a deterministic analysis, three months expected
medical care costs per patient with candidiasis were: US$42.743
for caspofungine, US$30.972 for voriconazole and US$36.736
for amphotericin B. The costs per patient with aspergillosis were:
US$49.962 for caspofungine, US$57.378 for voriconazole and
US$72.834 for amphotericin B. From a hypothetical patient
cohort of 1.000 patients with candidiasis, the ICER was
US$272.597 when voriconazole was used against amphotericin
B (US$ 272.6 per patient). The ICER in the aspergillosis model
was US$206.071 when voriconazole was used against ampho-
tericin B (US$ 206.1 per patient). Acceptability curves showed
that voriconazole was the antifungal treatment most cost–
effective in comparison with the two other treatments with 
a mean of 70% of certainty (with independence of the willing-
ness to pay amount). CONCLUSIONS: The use of voriconazole
in the treatment of candidiasis and invasive aspergillosis is a
more cost–effective therapeutic alternative than amphotericin B
and caspofungine, therefore, voriconazole should be the option
to be used as the ﬁrst line treatment in the Mexican health
system.
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OBJECTIVE: To assess the economic burden of gastroenteritis
and, in particular, rotavirus-associated disease among children
aged ﬁve years old and under, from the perspective of the health
service, parents and society. METHOD: Over a period of three
rotavirus seasons, stool samples were collected from 223 chil-
dren who presented at GP surgeries with diarrhoea and vomit-
ing. Parents were asked to complete a questionnaire detailing
severity of illness, health care resource use, personal medical
expenses, changes in child care patterns and associated costs, and
lost income due to their child’s illness. Data were analysed as a
whole to establish the cost of illness of gastroenteritis and sepa-
rately in terms of rotavirus and other viral strains. RESULTS: A
total of 48% of the sample had rotavirus acute gastroenteritis;
a further 21% had other virus-associated gastrointestinal
disease. The average total cost of a child presenting with gas-
troenteritis and rotavirus-gastroenteritis ranged between
£60–£176 and £59–£169 per episode, respectively, depending on
the perspective. The annual cost of ‘normal’ childhood illness
was estimated to be between £205 and £323. Given the preva-
lence and severity of the disease, the estimate additional burden
of gastroenteritis to society is £75.2 million per year, and for
rotavirus gastroenteritis it is £57.2 million per year. CONCLU-
SIONS: Due to the nature and prevalence of rotavirus the total
burden of illness is considerable. As well as being a major incon-
venience to parents and children, it would appear that there is a
considerable amount of cost shifting between the health service,
parents and society. Some of the economic cost of the illness may
be constrained with an immunisation programme; work is cur-
rently being undertaken to model the cost effectiveness of vacci-
nation within the UK context.
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OBJECTIVES: To estimate the nationwide annual cost for the
treatment of patients hospitalized with methicillin-resistant
Staphylococcus aureus (MRSA) infections in the United States.
METHODS: An extensive literature search was conducted in
order to identify recent studies estimating the direct medical costs
associated with MRSA infections in US hospitals. The range of
the annual cost of MRSA infections was constructed by multi-
plying the estimated number of annual discharges due to MRSA
infections by the highest and lowest cost per case estimates 
of MRSA bacteremia and S aureus pneumonia infections.
RESULTS: CDC estimated that in 2000 approximately 290,000
US patients were hospitalized with an S aureus infection and that
41.5%, or 120,000 of these were MRSA infections. The most
common types of MRSA infections are skin and skin structure
infections (SSSI), bacteremia, and lower respiratory tract infec-
tions. Abramson and Sexton estimated the direct medical costs
associated with MRSA bacteremia to be $27,083 per case. Enge-
mann et al. estimated the direct medical costs associated with an
SSSI due to MRSA to be $28,308 per case. Rubin et al. estimated
the direct medical costs associated with S aureus pneumonia to
be $34,900 per case. The average cost of an MRSA-related infec-
tion, based on cited studies, ranged from $27,083 to $34,900
per case. Assuming 120,000 annual MRSA infection related hos-
pital discharges, we estimate that the annual nationwide cost for
the treatment of patients hospitalized with an MRSA infection
in the US to be in the range of $3.2 billion to 4.2 billion. CON-
CLUSION: The annual cost for the treatment of MRSA infec-
tions incurs a signiﬁcant economic burden on the US health care
system. Strategies to minimize hospital costs relating to MRSA
infection should be critical to the management of this economic
burden placed on US hospitals.
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OUTPATIENT COMMUNITY-ACQUIRED PNEUMONIA IN 
NON-ELDERLY ADULTS: UTILIZATION AND COST
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OBJECTIVE: To examine utilization and cost of services in the
outpatient treatment of community-acquired pneumonia (CAP)
among non-elderly adults. METHODS: We analyzed claims
